T M Balogun1, S Emmanuel, K O Wright. 1. Department of Haematology & Blood Transfusion, Lagos State University Teaching Hospital, 1-5 Oba Akinjobi Road, P.M.B.21105, Ikeja, Lagos, Nigeria. taiwo_modupe@yahoo.com
Abstract
BACKGROUND: Hepatitis C virus (HCV) co infection is reported common in HIV positive individuals and also responsible for increasing morbidity and mortality among them. OBJECTIVE: This study was undertaken to determine the prevalence of antibodies to HCV (anti- HCV) among HIV positive patients. METHODS: This cross sectional study was carried out among HIV positive patients and HIV negative blood donors. HIV infection was diagnosed in patients using Determine HIV- 1/2 rapid kits and Elisa based immunocombfirm, while Dialab Elisa kits were used for screening blood donors for HIV and also assaying anti HCV in all subjects. RESULTS: Anti-HCV was detected in 14.7% of patients and 1.1% of HIV negative blood donors. HIV/HCV co-infection rate was highest in the 30-39 years age group (P > 0.05). CONCLUSION: Findings demonstrate a high prevalence with 13 fold higher risk of HCV co infection among HIV-positive patients.
BACKGROUND:Hepatitis C virus (HCV) co infection is reported common in HIV positive individuals and also responsible for increasing morbidity and mortality among them. OBJECTIVE: This study was undertaken to determine the prevalence of antibodies to HCV (anti- HCV) among HIV positive patients. METHODS: This cross sectional study was carried out among HIV positive patients and HIV negative blood donors. HIV infection was diagnosed in patients using Determine HIV- 1/2 rapid kits and Elisa based immunocombfirm, while Dialab Elisa kits were used for screening blood donors for HIV and also assaying anti HCV in all subjects. RESULTS: Anti-HCV was detected in 14.7% of patients and 1.1% of HIV negative blood donors. HIV/HCV co-infection rate was highest in the 30-39 years age group (P > 0.05). CONCLUSION: Findings demonstrate a high prevalence with 13 fold higher risk of HCV co infection among HIV-positivepatients.
Authors: Joseph C Forbi; Michael A Purdy; David S Campo; Gilberto Vaughan; Zoya E Dimitrova; Lilia M Ganova-Raeva; Guo-Liang Xia; Yury E Khudyakov Journal: J Gen Virol Date: 2012-03-28 Impact factor: 3.891